2023 World Conference on Lung Cancer (Posters)-EP14.02. Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies

EP14.02. Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies - PDF(Slides)

Back to course

Pdf Summary

A study presented by Hao Xiuxiu of Shanghai Chest Hospital in China focused on the use of neoadjuvant immune checkpoint inhibitor (ICI) therapy followed by resection for patients with locally advanced thymic malignancies. The study aimed to address the lack of exploration in this area and to assess the therapeutic effects of ICI-based therapy as a second-line treatment in patients with thymic carcinomas.<br /><br />The study included patients with potentially unresectable thymic malignancies who received neoadjuvant therapy containing immune checkpoint inhibitors. The primary outcome measured was the objective response rate, and secondary outcomes included the complete resection rate, perioperative outcomes, and progression-free survival.<br /><br />The results showed that among the patients, 2 had thymomas, 9 had thymic carcinomas, and 1 had a neuroendocrine tumor of the thymus. The objective response rate for thymic carcinoma was 55.6% for first-line treatment and 50.0% for second-line treatment. The complete resection rate was 66.7%, with a higher rate observed in responders compared to non-responders.<br /><br />The study also found that the progression-free survival in all patients was 17 months, with a 1-year progression-free survival rate of 75%. Responders to ICI-based therapy had a better progression-free survival and 1-year progression-free survival compared to non-responders.<br /><br />Based on these findings, the study concluded that neoadjuvant therapy containing ICI has promising objective activity in patients with locally advanced thymic carcinomas. Patients who respond well to ICI-based therapy have a better chance of achieving complete resection and survival. Therefore, neoadjuvant ICI-based therapy should be further investigated in future clinical trials for patients with advanced thymic carcinomas.

Asset Subtitle

Xiuxiu Hao

Meta Tag

Speaker Xiuxiu Hao

Topic Thymic Malignancy

Keywords

neoadjuvant immune checkpoint inhibitor therapy

resection

locally advanced thymic malignancies

thymic carcinomas

ICI-based therapy

objective response rate

complete resection rate

progression-free survival

responders

clinical trials